[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.172.195.82. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
This Month in Archives of Dermatology
December 2006

This Month in Archives of Dermatology

Author Affiliations
 

ROBIN L.TRAVERSMD

Arch Dermatol. 2006;142(12):1545. doi:10.1001/archderm.142.12.1545

The hypothalamic-pituitary-adrenal axis may be suppressed by topical steroids to an extent related to the potency of the steroid, the frequency of application, body surface area, and the skin's barrier function. In this multicenter, multiple-dose, open-label study, Schlessinger et al investigated the systemic and topical safety of a new super high–potency formulation of fluocinonide cream, 0.1%, in pediatric patients with clinically diagnosed atopic dermatitis. For a 2-week course of therapy, once-daily application was found to be as effective as twice-daily application, with no hypothalamic-pituitary-adrenal axis suppression.

See Article

The term cutaneous lymphoid hyperplasia (CLH) has been used to describe the benign end of the spectrum of cutaneous lymphoproliferative disorders, with cutaneous lymphoma at the malignant end. Most commonly presenting on the face, CLH consists histologically of a mixture of B and T lymphocytes. In this case series, Bergman et al demonstrate that with solitary facial CLH, the differentiation between pseudolymphoma and lymphoma may prove difficult. Although spontaneous regression following incisional biopsy may be a reassuring finding, careful clinical follow-up is warranted.

×